Biogen Plans To File BLA For Hemophilia B Drug In 2013
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen announced Phase III results for its hemophilia B drug, a potential competitor to Pfizer’s BeneFIX and the first offering in its hemophilia franchise.